Phase III failure of Rovi's Nautiol for diabetic foot ulcers scuppers filing plans
This article was originally published in Scrip
Executive Summary
Laboratorios Farmacéuticos Rovi's injectable low-molecular weight heparin Nautiol (also known as Hibor; bemiparin) failed to heal or improve diabetic foot ulcers compared with placebo, show top-line Phase III trial results. These data are insufficient to support a regulatory filing, the Spanish company told Scrip.